Wester A, Attar R, Mohammad MA, et al. - Researchers investigated how baseline anemia influenced a contemporary acute coronary syndrome (ACS) population in the era of predominant radial artery access, potent P2Y12 inhibition, and rare use of glycoprotein IIb/IIIa inhibitors. The participants were from the VALIDATE-SWEDEHEART (Bivalirudin Versus Heparin in ST-Segment and Non–ST-Segment Elevation Myocardial Infarction in Patients on Modern Antiplatelet Therapy in the Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies Registry) trial. A total of 5,482 ACS patients who underwent percutaneous coronary intervention between 2014 and 2016, without missing values for hemoglobin, were analyzed. Higher rates of 180-day mortality, myocardial reinfarction, and major bleeding were observed among ACS patients with anemia. Patients with a hemoglobin value < 100 g/L, having approximately 10 times higher mortality rate, exhibited these outcomes in the most pronounced way. To maximize benefit and minimize patient risk, it is justifiable to adopt a multidisciplinary approach.